2,3,5α-Trihydroxy-2-hydroxymethyl-1α-cyclopentane acetic acid 5γ -lactone derivatives

ABSTRACT

The present specification provides novel intermediates and novel processes for the synthesis of Thromboxane B 2  11a-homo-11a-oxa-PGF 2 α), its 15-epimer, and various carboxyl derivatives thereof. In particular, there are disclosed various bicyclic tetrahydrofuran-containing lactones useful in the above processes, and corresponding acyclic lactones.

The present application is a divisional application of Ser. No. 676,893, filed Apr. 14, 1976, issued as U.S. Pat. No. 4,048,194 on Sept. 13, 1977.

The present invention relates to Thromboxane B₂ and associated intermediates and processes for which the essential material constituting disclosure therefor is incorporated by reference here from Ser. No. 676,890, filed Apr. 14, 1976, issued as U.S. Pat. No. 4,020,173 on Apr. 26, 1977. 

I claim:
 1. A thromboxane intermediate of the formula ##STR1## wherein R₃₁ is a hydroxy-hydrogen replacing group selected from the group consisting of R₉, R₁₀, and R₃₄ ;wherein R₉ is an acyl protecting group selected from the group consisting of (a) benzoyl; (b) benzoyl substituted with one to 5 alkyl of one to 4 carbon atoms, inclusive, phenylalkyl of 7 to 12 carbon atoms, inclusive, or nitro, with the proviso that not more than 2 substituents are other than alkyl, and that the total number of carbon atoms in the substituents does not exceed 10 carbon atoms, with the further proviso that the substituents are the same or different. (c) benzoyl substituted with alkoxycarbonyl of 2 to 5 carbon atoms, inclusive; (d) naphthoyl; (e) naphthoyl substituted with one to 9, inclusive, alkyl of one to 4 carbon atoms, inclusive, phenylalkyl of 7 to 10 carbon atoms, inclusive, or nitro, with the proviso that not more than 2 substituents on either of the fused aromatic rings are other than alkyl and that the total number of carbon atoms in the substituents on either of the fused aromatic rings does not exceed 10 carbon atoms, with the further proviso that the various substituents are the same or different; and (f) alkanoyl of 2 to 12 carbon atoms, inclusive; Wherein R₁₀ is a blocking group selected from the group consisting of (a) tetrahydropyranyl; (b) tetrahydrofuranyl; and (c) a group of the formula

    --C(OR.sub.11)(R.sub.12)--CH(R.sub.13)(R.sub.14),

wherein R₁₁ is alkyl of one to 18 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl or phenyl substituted with one to 3 alkyl of one to 4 carbon atoms, inclusive, wherein R₁₂ and R₁₃ are alkyl of one to 4 carbon atoms, inclusive, phenyl, phenyl substituted with one, 2, or 3 alkyl of one to 4 carbon atoms, inclusive, or when R₁₂ and R₁₃ are taken together --(CH₂)_(a) -- or --(CH₂)_(b) --O--(CH₂)_(c), wherein a is 3, 4, or 5, or b is one, 2, or 3, and c is one, 2, or 3, with the proviso that b plus c is 2, 3, or 4, with the further proviso that R₁₂ and R₁₃ may be the same or different, and wherein R₁₄ is hydrogen or phenyl; wherein R₃₄ is an arylmethyl hydroxy-hydrogen replacing group selected from the group consisting of (a) benzyl, (b) benzyl substituted by one to five alkyl of one to four carbon atoms, inclusive, chloro, bromo, iodo, fluoro, nitro, phenylalkyl of 7 to 12 carbon atoms, inclusive, with the further proviso that the various substituents are the same or different, (c) benzhydryl, (d) benzhydryl substituted by one to ten alkyl of one to four carbon atoms, inclusive, chloro, bromo, iodo, fluoro, nitro, phenylalkyl of 7 to 12 carbon atoms, inclusive, (e) trityl, and (f) trityl substituted by one to 15 alkyl of one to four carbon atoms, inclusive, chloro, bromo, iodo, fluoro, nitro, phenylalkyl of 7 to 12 carbon atoms, inclusive.
 2. (2S,3R)- or (2R,3S)-2,3,5α-trihydroxy-2-benzoyloxymethyl-1α-cyclopentaneacetic acid 5γ-lactone, a thromboxane intermediate according to claim
 1. 